 |
|
Invasive methods unnecessary for prostate cancer radiation therapy treatment planning
May 21, 2008Modern 3-D computed tomography (CT) is an effective method for locating the prostatic apex for radiation therapy treatment planning in prostate cancer patients because it eliminates the need for an invasive procedure and the related side effects, according to a study in the May 1 issue of the International Journal of Radiation Oncology*Biology*Physics.
Retrograde urethrography, which involves inserting a catheter into the male urethra to inject contrast, is the standard method used to identify the area of the prostate to be treated with radiation. However, this method is invasive and uncomfortable for patients and comes with risks of side effects, such as urethral injury and infection, as well as additional costs.
Researchers at the University of Texas Health Science Center at San Antonio departments of Radiation Oncology and Urology conducted this study to determine if knowledge of the anatomic relationships of the prostatic base and the prostatic apex along with modern 3-D CT planning, could be used as a substitute for retrograde urethrography.
Fifteen patients underwent a CT simulation both with and without bladder, urethral and rectal contrast. The prostatic base and apex were identified easily and consistently on both scans by taking a side view of the patient and drawing a line from the pubic bone straight down to the floor of the pelvis. The process was repeated and confirmed in another 57 patients, leading researchers to determine that it is not necessary to subject a patient to a urinary catheter for contrast delivery.
"By using CT scans to find the prostatic apex, patients are happier and we have the same results," said Gregory Swanson, M.D., associate professor of radiation oncology at the University of Texas Health Science Center at San Antonio and one of the study's authors. "I stopped doing contrast in 1995 or 1996 when I realized that I knew where the prostate was without using invasive methods. I have been successful in using CT since then."
American Society for Therapeutic Radiology and Oncology
Fifteen patients underwent a CT simulation both with and without bladder, urethral and rectal contrast. The prostatic base and apex were identified easily and consistently on both scans by taking a side view of the patient and drawing a line from the pubic bone straight down to the floor of the pelvis. The process was repeated and confirmed in another 57 patients, leading researchers to determine that it is not necessary to subject a patient to a urinary catheter for contrast delivery.
"By using CT scans to find the prostatic apex, patients are happier and we have the same results," said Gregory Swanson, M.D., associate professor of radiation oncology at the University of Texas Health Science Center at San Antonio and one of the study's authors. "I stopped doing contrast in 1995 or 1996 when I realized that I knew where the prostate was without using invasive methods. I have been successful in using CT since then."
American Society for Therapeutic Radiology and Oncology
Prostate Cancer News and Current Prostate Cancer Events RSSExposure to Agent Orange linked to prostate cancer in Vietnam veterans
UC Davis Cancer Center physicians today released results of research showing that Vietnam War veterans exposed to Agent Orange have greatly increased risks of prostate cancer and even greater risks of getting the most aggressive form of the disease as compared to those who were not exposed.
Disparities in prostate cancer treatment suggest ways to improve care
Quality of care varies greatly for the treatment of men with early-stage prostate cancer by region of the country and category of health care facility, suggesting the potential for improved patient outcomes with more standard treatment protocols.
NewYork-Presbyterian/Columbia leads research into robotic surgery for kidney cancer
Clinical research at NewYork-Presbyterian Hospital/Columbia University Medical Center is helping bring the advantages of robotic surgery, including reduced pain and quicker recovery, to kidney cancer patients.
Prostate cancer patients undergoing hormone therapy may experience cognitive effects
A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients-- such as in the ability to recall and concentrate.
First worldwide analysis of cancer survival finds wide variation between countries
Cancer survival varies widely between countries according to a worldwide study published online today in Lancet Oncology.* More than 100 investigators contributed to the study.
Possible link found between x-rays and prostate cancer
Researchers at The University of Nottingham have shown an association between certain past diagnostic radiation procedures and an increased risk of young-onset prostate cancer - a rare form of prostate cancer which affects about 10 per cent of all men diagnosed with the disease.
Prostate cancer vaccines more effective with hormone therapy
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
Counting tumor cells in blood predicts treatment benefit in prostate cancer
Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show.
Elevated biomarkers predict risk for prostate cancer recurrence
A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.
Researchers identify promising cancer drug target in prostate tumors
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
More Prostate Cancer News Articles
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh, Janet Farrar Worthington |
 | You Can Beat Prostate Cancer by Robert J. Marckini |
 | The Vitamin D Cure by James Dowd, Diane Stafford |
 | A Primer on Prostate Cancer: The Empowered Patient's Guide by Stephen Strum, Donna L. Pogliano |
 | Eat to Beat Prostate Cancer Cookbook by David Ricketts |
 | Prostate Health in 90 Days by Larry Clapp |
 | Prostate And Cancer: A Family Guide To Diagnosis, Treatment And Survival (3rd Edition) by Sheldon Marks |
 | Prostate Cancer for Dummies by Paul H. Lange, Christine Adamec, Christine Adamec |
 | Dr. Peter Scardino's Prostate Book: The Complete Guide to Overcoming Prostate Cancer, Prostatitis, and BPH by Peter Scardino, Judith Kelman |
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer by Patrick C. Walsh, Janet Farrar Worthington |
| © 2008 BrightSurf.com |